Freeline Therapeutics Holdings plc
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About FRLN
Freeline Therapeutics Holdings plc is a clinical-stage biotechnology company. The Company is developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from chronic debilitating diseases. It uses its rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into a patient’s bloodstream. It is advancing FLT201, a differentiated gene therapy candidate that delivers a novel transgene, in a Phase 1/2 clinical trial in people with Gaucher disease type 1. Therapeutic AAV vectors consist of two main components: the capsid and the expression cassette (that contains the gene and the promoter). It has additional programs in research, including one focused on GBA1-linked Parkinson’s disease that leverages the same novel transgene as FLT201.
Buy US stocks in Australia starting with FRLN. Open an account and start investing today!
-
-
-
-
-
-
-
-
-
Ready to start your investing journey with Stake?
Open an accountFRLN FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in FRLN
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in FRLN
on Stake
Buy FRLN from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of FRLN from only US$10 with fractional shares
